HANGZHOU TIGE TECHNOLOGY

Hangzhou Tige Technology, a subsidiary of the renowned Tigermed Group, stands as a leading player in the clinical research and development sector. Specializing in a full suite of Contract Research Organization (CRO) capabilities, Hangzhou Tige Technology is dedicated to supporting clients in their clinical development journey with excellence and commitment. The company's core services encompass preclinical and clinical development, post-marketing studies, real-world data analysis, and integrated capabilities across a wide range of therapeutic areas such as oncology, infectious diseases, cardiovascular, and more.

With a global workforce of over 10,000 employees and serving more than 3,200 customers worldwide, Hangzhou Tige Technology has established a strong market presence through its innovative approach and top-notch technology platform. The company's commitment to advancing human health by delivering life-changing therapies is underscored by its track record of successfully supporting the development of over 117 innovative drugs. Noteworthy achievements include its involvement in rare disease research, cell and gene therapy advancements, and its extensive global network of subsidiaries and offices across Asia, the US, Europe, Latin America, and Africa.

Founded in 2004, Hangzhou Tige Technology has evolved into a trusted partner for the global biopharmaceutical and medical device industries. Embodying a mission to accelerate the launch of innovative healthcare products, the company places a strong emphasis on quality, expertise, and cost-effective solutions. With a focus on delivering excellence in clinical research and development, Hangzhou Tige Technology continues to expand its geographic presence and enhance its service offerings to meet the evolving needs of its diverse customer base. As the company looks towards the future, it remains dedicated to driving healthcare innovation and making a meaningful impact on patient outcomes worldwide.